CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis Delta and 96 weeks of posttreatment follow-up
DOI 10.1055/s-0045-1810987
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH Wedemeyer, S Aleman, A Blank, P Andreone, P Bogomolov, V Chulanov, N Mamonova, N Geyvandova, V Morozov, O Sagalova, T Stepanova, A Berger, S Ciesek, K Deterding, A Lichtman, D Manuilov, R-C Mercier, S Arterburn, F Christian-Cox, S Tseng, A Osinusi, J Sculze zur Wiesch, M Cornberg, S Zeuzem, M Bru…
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2025
Jahrgang / SeitenJg. 63 · S. e557-e558
Kernaussage aus der Literatur
Abstract-Vorschau
Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis Delta and 96 weeks of posttreatment follow-up
Zitieren
Zitierempfehlung
H Wedemeyer, S Aleman, A Blank, P Andreone, P Bogomolov, V Chulanov, N Mamonova, N Geyvandova, V Morozov, O Sagalova, T Stepanova, A Berger, S Ciesek, K Deterding, A Lichtman, D Manuilov, R-C Mercier, S Arterburn, F Christian-Cox, S Tseng, A Osinusi, J Sculze… (2025) Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis Delta and 96 weeks of posttreatment follow-up. Zeitschrift für Gastroenterologie, 63 (08), e557-e558. https://doi.org/10.1055/s-0045-1810987
Mit CareLit weiterarbeiten